The presence of genetic thrombophilia markers such as FVL, PGM 20210A mutation, AT III deficiency, and antiphospholipid antibodies significantly increases a patient's risk of thrombotic event [20, 21]. This evidence concerns the gene VCAN and thrombophilia.